Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Share-based Compensation (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Share-based Compensation for 2 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation changed 0.0% to $100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $409544.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $163772.0 for FY2025, 79.9% down from the prior year.
  • Share-based Compensation for Q4 2025 was $100000.0 at Neuphoria Therapeutics, down from $111277.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $111277.0 in Q3 2025, with the low at $26736.0 in Q3 2024.